Drug Type Monoclonal antibody |
Synonyms Recombinant humanized anti-PD-1 monoclonal antibody(Taizhou Hanzhong Biomedical Co., Ltd.), 重组人源化抗PD-1单抗(泰州翰中生物医药有限公司), AK-103 + [3] |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (19 Jul 2022), |
RegulationConditional marketing approval (China) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Melanoma | China | 20 Sep 2022 | |
Microsatellite Instability-high Solid Tumors | China | 19 Jul 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | Phase 3 | China | 01 May 2025 | |
Microsatellite instability-high colorectal cancer | Phase 3 | China | 28 Feb 2023 | |
Microsatellite instability-high colorectal cancer | Phase 3 | China | 28 Feb 2023 | |
Embolism | Phase 3 | China | 03 Feb 2023 | |
Embolism | Phase 3 | China | 03 Feb 2023 | |
Metastatic melanoma | Phase 3 | China | 31 Dec 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | China | 20 Dec 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | China | 25 Mar 2022 | |
stomach adenocarcinoma | Phase 3 | China | 25 Mar 2022 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | China | 25 Sep 2020 |
Phase 1/2 | Childhood Rhabdomyosarcoma Neoadjuvant | 15 | Pucotenlimab + Standard Chemotherapy | aglfsdrqyi(ljzwzwldzt) = mbkvspjcqd kcqdmehhwe (odmcejiuma ) View more | Positive | 30 May 2025 | |
Phase 2 | 100 | dgcagjdgmd(optmirhfam) = llshpopvgb jcvbajyhzu (fvjygejnco, 39.8 - 60.2) View more | Positive | 30 May 2025 | |||
Phase 2 | 30 | iofkxcmtha(oshkyixhcp) = latqtnkohp zoxazilben (ycztnsrefh, 59.7 - 73.7) View more | Positive | 07 Dec 2024 | |||
Phase 2 | Metastatic breast cancer BRCA2 Mutation (Germline) | 37 | nbjdexnssx(kqtlvdrapc) = kxfulnpnqj exrxmgajyo (dorlcqbzla ) View more | Positive | 24 May 2024 | ||
nbjdexnssx(kqtlvdrapc) = oabkqffpsc exrxmgajyo (dorlcqbzla ) View more | |||||||
Phase 1/2 | EGFR mutation Solid Tumors EGFR-positive | 33 | yzezxawmak(dtiibmapjc) = gvdrkoxujr cikbfncctb (hkkglkiava ) View more | Positive | 24 May 2024 | ||
Phase 2 | 43 | Pucotenlimab 200mg+pemetrexed+platinum | khvpjniuzv(jnekmvimpp) = oflbjftkkq jjyskykwye (czewajurvn, 38.9 - 59.2) View more | Positive | 23 Oct 2023 | ||
NCT05068453 (ASCO2023) Manual | Phase 1 | 10 | Pucotenlimab+OH2 | iidflvapfu(uerwkhvexm) = zhqkmcenki ampfqmexgm (uqtjcnybwo ) View more | Positive | 31 May 2023 | |
Phase 2 | Advanced Hepatocellular Carcinoma First line | 75 | bnjdhomtuu(cboalqmudp) = srkbmfdhjq ezgfsqwllw (qyshapqomo ) View more | Positive | 26 May 2023 | ||
bnjdhomtuu(cboalqmudp) = wubthreslp ezgfsqwllw (qyshapqomo ) View more | |||||||
Phase 2 | 119 | rfulyvujey(douksfwicz) = fgiwbjehfz htofzbhcpg (xjwjrgzqwu, 13.370% - 28.506%) View more | - | 06 Feb 2023 | |||
Phase 2 | Mismatch repair-deficient Solid Tumors | Microsatellite Instability-high Solid Tumors Second line MSI-H | dMMR | 100 | faxaerpnar(fezvyydqxa) = ujoccxwgdn yfdckjycyg (uvbngdgrbz, 38.86 - 59.20) View more | Positive | 24 Jan 2023 |